Consumer drug advertising is favorite culprit in rising Rx costs

Share this article:

Consumer drug advertising remains corporate benefit managers' favorite culprit in rising prescription drug costs, according to an Arxcel survey. Forty-five percent cited DTC as the top cause of rising costs, compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%, and an aging population ranked third, at 17%. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions